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A B S T R A C T
Post-smolt Atlantic salmon (Salmo salar) were fed with standard feed added one of five concentrations of either
pure deoxynivalenol (DON; 0.5–6mg/kg) or pure ochratoxin A (OTA; 0.2–2.4mg/kg), or no added toxins for up
to 8 weeks. Performance effects (feed intake, feed efficiency, gain, length and condition factor), various clinical
biochemical parameters, packed cell volume and vaccination response against Aeromonas salmonicidae were all
inversely correlated with DON dose, whereas relative liver weight increased with DON dose. In fish fed OTA,
however, the effects at the doses tested were rather small. We observed no effects of OTA exposure on perfor-
mance parameters, but some clinical biochemical parameters tended to increase with OTA dose primarily at 3
weeks, and compared with controls OTA exposure caused increased mRNA expression of two immune markers in
the spleen. No liver histopathological effects were found from DON or OTA exposure. For DON, we derived a
BMDL20 of 0.3mg/kg feed for reduced total protein in plasma, a BMDL5 of 0.5mg/kg feed for reduced condition
factor, and a NOAEL of 1 mg/kg feed for DON. For OTA, a BMDL or NOAEL could not be derived (> 2.4mg/kg).
1. Introduction
The mycotoxins deoxynivalenol (DON) and ochratoxin A (OTA) may
occur in cereal based animal feed or human food and constitute a health
risk both to farmed animals and humans. DON belongs to the group of
trichothecenes that frequently occur in cereals infected by Fusarium
species in temperate areas. Major health problems caused by DON in-
gestion in animals are feed refusal and reduced weight gain. Acute ef-
fect in humans is vomiting. At lower long-term intake DON may also
impair immune functions (VKM, 2013; EFSA, 2017a). OTA may be
present in sub-optimally stored feed and food commodities worldwide
due to infection of mould species in genera Penicillium and Aspergillus.
The main health effects of OTA in mammals are kidney toxicity as well
as immune suppression (EFSA, 2004; EFSA, 2006).
An increased use of cereal ingredients in fish feed and the fact that
DON and OTA both have been found in current fish feed (VKM, 2013;
Pietsch et al., 2013; Nácher-Mestre et al., 2015) makes knowledge on
health effects and toxicokinetics of these mycotoxins in farmed fish
important. We recently published a study on tissue distribution and
elimination of these toxins in Atlantic salmon, Salmo salar (Bernhoft
et al., 2017). Although there are some studies available on health ef-
fects of DON and OTA on farmed fish, there are, to our knowledge, none
on Atlantic salmon.
The mycotoxins studied, DON and OTA, are chemically quite dif-
ferent compounds, and they are produced by mould from different
genera. Toxicologically, however, their target of toxicity is related as
they both inhibit protein synthesis, though with different molecular
modes of action (EFSA, 2004; EFSA, 2006; EFSA, 2017a). Both toxins
may impair growth performance, immune markers or immune function,
and cause histopathological changes in fish (EFSA, 2017a). Further-
more, DON and OTA may co-occur in cereals used in feed for fish. Thus,
a comparison of their effect profile in fish was considered appropriate.
Atlantic salmon is the main species in Norwegian fish farming and
correspondingly, also an important species in the Norwegian fish ex-
port. The objectives of the present study were to examine and compare
effects of DON and OTA on growth performance, selected clinical bio-
chemical and immunological parameters including vaccination re-
sponse, and histopathology, in juvenile post-smolt Atlantic salmon. We
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conducted benchmark dose (BMD) modeling of observed effects, and
determined benchmark dose lower confidence limit (BMDL) and no-
observed-adverse-effect-levels (NOAEL) after 8 weeks exposure.
2. Materials and methods
2.1. Study design and animal ethics
The fish study was conducted at Skretting ARC Research Station
Lerang, Stavanger, Norway. The research station is approved by the
Norwegian Animal Research Authority and the trial was conducted in
accordance with the current animal welfare regulations in Norway
(FOR-1996-01-15-23). The experiment was approved by the responsible
person for animal ethics at the facility. It was combined with a study on
toxicokinetics published separately (Bernhoft et al., 2017). The present
study included five dosage groups per toxin and a control group. Ju-
venile post-smolt salmon (SalmoBreed, 12 months old, both genders)
were randomly distributed into 22 circular tanks (100 L) supplied with
flow-through seawater at 12 °C and exposed to light 24 h a day. Each
tank contained 25 fish with initial average body weight varying from
56.8 to 58.9 g between the tanks. All experiments were performed in
duplicate with two tanks per dose group and toxin. The order of tanks
was randomised. After one day of acclimatisation, the fish were fed
with the experimental diets for 8 weeks.
Feeding was done automatically during three 2-h periods per day
(08:00–10:00, 12:00–14:00 and 22:00–24:00). The amount of feed was
adjusted to the number and size of the fish and the daily feed ration
given was in slight excess of the expected voluntary feed intake. Feed
pellets fell through the water column in the tank for approximately
1min. The not-ingested spilled rest was collected on a sieve above the
drain for effluent water at the bottom of the tank. This feed rest was
removed after each 2-h feeding period, dried, weighed and subtracted
from the total daily feed supply of each tank, to calculate actual feed
intake per fish.
2.2. Experimental fish feed
The feed was a standard Atlantic salmon feed (Spirit 3 mm,
Skretting, Stavanger, Norway) containing 48% crude protein and 25%
crude fat. At the time when the study was conducted, Skretting ARC ran
a monitoring programme for feed and feed ingredients which included
several mycotoxins including DON, OTA, fumonisins, zearalenone, and
aflatoxins B1, B2, G1 and G2. In general, most analysed samples were
below the limit of detections for the mycotoxins, and if present, they
were below acceptable concentrations. Thus, that the experimental feed
contained unknown mycotoxins which could have influenced the re-
sults of the study is not likely.
The pellets were coated with DON or OTA providing diets from
relatively low to high content of mycotoxin while not causing acute
toxic effects in the fish. DON (Biopure standard; deoxynivalenol lot
#06221Z, degree of purity 99.4%) was added to the pellets to achieve
0.5, 1.0, 2.0, 4.0 and 6.0mg/kg feed. OTA (Biopure standard ochra-
toxin A; lot #S07301Z, degree of purity 99.5%) was added to achieve
0.2, 0.4, 0.8, 1.6 and 2.4mg/kg feed. DON and OTA were purchased at
Romer Labs Diagnostic GmbH (Tulln, Austria). The concentrations of
DON and OTA covered the range of the guideline levels in EU and
Norway for fish feedingstuff, which are for DON 5 and 2mg/kg, re-
spectively, and for OTA 0.25 and 1 mg/kg, respectively (European
Commission, 2006; Norwegian Food Safety Authority, 2015).
DON and OTA were dissolved in 50mL 70% ethanol (DON: 2.5, 5,
10, 20 and 30 mg/50mL; OTA: 1, 2, 4, 8 and 12 mg/50mL; control:
50 mL without toxin) and coated on 5 kg of feed pellets by carefully
spraying the feed while moving it in a drum. Subsequently, the toxin-
containing pellets were coated with 25 g fish oil (0.5%) for stabilisation
while still rotating for another 3min. The fortified feeds were produced
3 weeks prior to trial start and stored at 4 °C.
Three representative samples (250 g) of each feed preparation were
collected for analysis of DON or OTA content by gas chromato-
graphy–mass spectrometry or high-pressure liquid chromatography
with fluorescence detection, respectively, as described by Bernhoft
et al. (2017). The measured DON concentrations (mean (and SD) for
n=3) in the diets were 0.53 (0.02) mg/kg, 1.27 (0.41) mg/kg, 2.42
(0.09) mg/kg feed, 3.48 (0.17) mg/kg and 5.53 (0.10) mg/kg feed,
respectively. The measured OTA concentrations (mean (and SD) for
n=3) in the diets were 0.18 (0.00) mg/kg, 0.34 (0.00) mg/kg, 0.72
(0.03) mg/kg feed, 1.49 (0.14) mg/kg and 2.00 (0.29) mg/kg feed,
respectively. The control feed did not contain any detectable DON
(<20 μg/kg) or OTA (<0.015 μg/kg).
The analysed average feed concentrations of DON and OTA based
on three samples per concentrations were slightly different from those
based on added amounts, and thus estimated values. As analysed values
were based on a relatively low number of parallel samples, and showed
a certain variation probably primarily due to somewhat uneven dis-
tribution of the toxins in the pellets, we rely and relate to the estimated
toxin concentrations.
2.3. Sampling of fish
After 3, 6 and 8 weeks, 5 fish were collected from each tank, in total
10 fish for each diet group and sampling point. The fish were subse-
quently anaesthetised with 10mL Finquel 40 g/L in 5 L water. Their
weight and lengths were measured before they were killed. Blood was
immediately sampled and during the subsequent autopsy samples for
histological evaluation were prepared. Spleen tissue was put in
RNAlater™ (Invitrogen™) and kept cool for 24 h before frozen. Samples
from musculature, liver, bile and posterior kidney were frozen im-
mediately in dry ice and later stored at −20 °C until analysis.
Heparinized blood was centrifuged, and plasma was separated from the
cells and stored at −20 °C until analysis. At 8-weeks-sampling fresh
whole blood was also used for packed cell volume (haematocrit) mea-
surement, and a transversal section of the skin and musculature in-
cluding the lateral line and tissues from the gills, heart, liver, spleen and
mid kidney were put on formalin and fixed for at least 24 h before
processing.
The same sampling procedure was followed at each time point,
observing the same order of fish tanks and time schedule. Each sam-
pling took two consecutive days, from morning to afternoon on the first
day, and from morning to noon of the second day, independent of
feeding times.
2.4. Vaccination
At 3 weeks of exposure, i.e. immediately after the 1st sampling, the
fish received an intraperitoneal injection of a monovalent vaccine
against Aeromonas salmonicidae salmonicidae (courtesy Intervet Norbio/
Schering-Plough Animal Health). The inactivated whole-bacteria vac-
cine was formulated as a water-in-oil emulsion using mineral oil ad-
juvant.
2.5. Effect parameters
Feed intake was determined per tank per day. The number of fish
per tank was known, but not the exact biomass. Feed intake was cal-
culated as an average per fish per day, and was added up to yield the
weekly feed intake or the total feed intake during 3, 6 or 8 weeks for
each tank or treatment group.
Body weight and length were measured in sampled fish at the be-
ginning of the experiment and at 3, 6 and 8 weeks. Weight gain and
feed efficiency (weight gain/feed intake) after at 3, 6 and 8 weeks were
estimated from the averages of these data, assuming that the sampled
fish were representative of the whole treatment group.
Condition factor was calculated for each fish as 100 x body weight
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(g)/body length3 (cm)3.
Relative liver weight (hepatosomatic index) was calculated as the
percentage of body weight held by the liver.
The selected clinical biochemical parameters (aspartate amino-
transferase (AST), alanine aminotransferase (ALT), alkaline phospha-
tase, cholesterol, triglycerides, bile acids, total proteins, and albumin)
were analysed spectrophotometrically by using a Siemens Advia®1800
clinical biochemistry analyzer (Siemens Healthcare Diagnostics Inc.,
Tarrytown, NY, USA).
Packed cell volume was measured in heparinized blood in 32 μL Li-
heparinized glass capillary tubes, from Hirschmann, after centrifuga-
tion (Sigma 201M) at 10,000 rpm for 5min.
Enzyme linked immunosorbent assay (ELISA): Blood plasma sam-
ples were analysed for levels of IgM antibodies specific for A. salmoni-
cida using ELISA as described previously (Erdal and Reitan, 1992), with
minor modifications. Briefly, wells were coated with 100mL of soni-
cated whole cells of A. salmonicida type strain (NCIMB 3175/88) (5 μg
protein/mL). Sample plasma (1:200) was incubated at 4 °C overnight,
followed by incubation with a monoclonal antibody against rainbow
trout immunoglobulin (4C10:3) (reactive with Atlantic salmon im-
munoglobulin) (Thuvander et al., 1990) for 60min at room tempera-
ture. The plates were incubated with a sheep anti-mouse Ig conjugated
to peroxidase (NA 931, Amersham, UK) before adding the substrate,
tetramethylbenzidine (8622, Merck, Darmstadt, Germany). After
10min, the reaction was stopped by adding 5M H2SO4. The absorbance
of duplicate sample wells was read at 450 nm. A pooled plasma sample
from 24 Atlantic salmon hyper-immunized with A. salmonicida was run
as positive control on each plate. A pooled plasma sample of 44 un-
vaccinated Atlantic salmon served as negative control.
qRT-PCR analysis of selected immune genes consisting of gene
markers for immunoglobulin D (IgD), T-cell function (CD4, CD8), cy-
tokine interferon gamma (IFNγ), cell proliferation (Ki67): RNA was
extracted from spleen tissue stored in RNAlater using the RNeasy kit
(Qiagen, 74,106) according to the manufacturers' instructions.
Extracted RNA was quantified using NanoDrop ND-1000 (NanoDrop
Technologies), and cDNA prepared from identical amounts of RNA
employing the Quantitect Reverse Transcription kit (Qiagen, 205,313).
The qPCR was performed on Stratagene Mx3000 instruments (Agilent
Technologies) using Maxima SYBR Green/Rox qPCR Master Mix
(Fermentas K0221), employing the following temperature cycling: in-
itial 95 °C for 10min followed by 40 cycles of 95 °C/15s, 60 °C/15s,
72 °C/30s and ended by a melting curve analysis. Specifications of
primers for the gene expression analysis of spleen tissue are shown in
Table 1. Elongation factor 1ab (EF1ab) (Olsvik et al., 2005) was used as
reference gene, and results for the immune genes were expressed as
relative to EF1ab according to Pfaffl (2001). The EF1ab gene has been
used as reference gene under several different experimental conditions,
including viral (Lund et al., 2016) and bacterial (Løvoll et al., 2009)
infections. In the current study, under the specific experimental con-
ditions applied, the EF1ab did not vary significantly between feeding
groups at a given sampling time or between sampling times within a
given feeding group (data not shown). This was contrasted by the stu-
died genes, where raw Ct values showed statistical significant variation.
Histology: Formalin-fixed tissues were routinely processed and
embedded in paraffin 24–48 h after sampling. Tissues from the fish that
had received diets with the highest level of both toxins, fish that had
received OTA at 0.8 mg/kg and fish in the control group from the last
sampling were cut in ultrathin sections. These sections were depar-
affinized in xylene and rehydrated in graded alcohol baths before
staining with hematoxylin and eosin for examination in a light micro-
scope.
2.6. Statistics
Statistical analyses were performed using JMP® Pro 11.0.0.
(ANOVA, 2013 SAS Institute Inc., Cary, NC, USA). As most effect
variables were without Normal distribution according to Shapiro-Wilk
W test, the non-parametric Wilcoxon rank sum test was used to com-
pare the multiple treatment groups with the control group for the
various variables from sampling at 3, 6 and 8 weeks exposure.
Bonferoni correction was used to adjust for five comparisons per
parameter per toxin. Significance level was p < 0.01×5=p < 0.05.
Linear regression was used to identify linear dose-response effects of
DON and OTA. For linear regression analyses, the effect variables were
considered to be of satisfactory Normal distributions, except for AST
and ALT, which were Lognormal distributed and therefore log-trans-
formed. Adjusted RSquare was used to estimates the proportion of
variation in the response that can be attributed to the linear model
rather than to random error. To test for a linear dose-response of feed
efficiency, data from the three sampling time points were used, with
two replicates per dose (two tanks) yielding six data points per dose.
In addition, observations at the last sampling point (eight weeks
exposure), representing the longest exposure in our study, were used for
BMD modeling following the most recent guideline from EFSA (2017b).
Individual data were fit as continuous data on two families of (nested)
models: the Exponential and Hill models, using the EFSA benchmark
dose software (Proast, version 64.9 https://shiny-efsa.openanalytics.
eu/app/bmd). BMD models were selected or accepted based on the
Akaike information criterion (AIC), with a critical value of 2 units
difference. The best model was selected as the one with the lowest AIC.
When two models had the same AIC; the one giving the smallest con-
fidence interval for the BMD value was chosen. A dose-relationship was
considered significant if the best model had an AIC at least two units
lower than the null model (no dose response). The fit was considered
acceptable if the AIC was less than two units higher than that of the full
model. For performance data we used the default benchmark response
(BMR) for continuous data of 5% (BMDL05) (EFSA, 2017b). However,
due to the high variation level of clinical biochemical parameters,
packed cell volume and antibodies, we considered a BMR of 20% as
appropriate for deriving the BMDL (BMDL20) for these parameters.
3. Results
3.1. Mortality
All together 11 fish died or were removed due to reduced clinical
health during the study. These were individuals exposed to DON at
1mg/kg (3 fish) and 4mg/kg (1 fish), and to OTA at 0.2mg/kg (3 fish),
0.8 mg/kg (3 fish) and 2.4 mg/kg (1 fish). No fish died in the control
group. The dropouts were spread in time and tanks, and not found re-
lated to dose of the toxins. Thus, we considered that the death was
independent of toxin exposure.
Table 1
Specifications of primers for gene expression analysis of spleen tissue used in
the study of post-smolt Atlantic salmon exposed to deoxynivalenol or ochra-
toxin A in their feed for up to 8 weeks.
Target Gene Sequence 5→ 3′ Product size
(nt)/melting
temperature
(°C)
GenBank no.
IgD F-TGAACATCGCTGCTTCAAC 128/82.3 AF141607
R-CCAGCACAGCACTGTCTCC
CD4 F-GCCCCTGAAGTCCAACGAC 84/80.1 NM_001146408
R-AGGCTTCTCTCACTGCGTCC
CD8 F-GTCTACAGCTGTGCATCAATCAA 117/83.2 NM_001123583
R-GGCTGTGGTCATTGGTGTAGT
IFNγ F-AAAACCTGTTTTCCCCAAGG 69/79.1 AY795563
R-TCCAGAACCACACTCATCCA
Ki67 F-GGGGAGGTTTTTCAGCAGTC 96/77.4 NM_001141409
R-AGTGGGTGCTGGAGGGTATT
EF1ab F-TGCCCCTCCAGGATGTCTAC 57/77.9 BG933853
R-CACGGCCCACAGGTACTG
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3.2. Performance (feed intake, growth and condition factor)
The average feed intake per fish per week for each dosage group
during the 8 weeks feeding period is shown in Fig. 1. In all groups, feed
intake dropped the 4th week, after vaccination of the fish. Total feed
consumption during the 8 weeks was 22% and 42% lower in fish ex-
posed to DON feed concentration of 4 and 6mg DON/kg feed, respec-
tively, than in control fish. For the fish fed 6mg DON/kg, the feed in-
take was lower during the whole toxin feeding period, but for the fish
fed 4mg DON/kg, the reduced feed intake was most distinct from 4 to 8
weeks. In addition, high DON exposure reduced feed efficiency, and a
significant dose-relationship between feed efficiency and DON dose was
found (p < 0.001, R2Adj 0.33) (Fig. 2).
Body weight increased during the 8-week study in all groups
(Table 2). However, weight gain was inversely correlated with DON
dose already after 3 weeks. The linear regression data are shown in
Table 3. The dose-related effect increased throughout the study from 3
to 8 weeks. When comparing toxin-exposed fish to controls, reduced
body weight was found in fish fed 6mg DON/kg feed already from 3
weeks exposure and through the experiment (Table 2). Body length was
inversely correlated with DON dose after 6 and 8 weeks exposure
(Table 3). Compared with controls, body length was smaller in fish fed
6mg DON/kg feed for 6 and 8 weeks.
The condition factor decreased with increasing DON dose from
week 3 (Tables 2 and 3). Compared with controls, condition factor was
lower in fish fed 6mg DON/kg feed for 6 weeks, and in fish fed 4 and
6mg DON/kg feed for 8 weeks.
In fish exposed to OTA, we observed no effects of exposure on feed
intake (Fig. 1), feed efficiency (Fig. 2), body weight, body length, or
condition factor (Tables 2 and 3).
3.3. DON effects on selected health indices
Fish exposed to DON had no dose-related effect on absolute liver
weight (Table 3). However, relative liver weight related to body weight
increased with DON concentration after 6 and 8 weeks (Table 3). Re-
lative liver weight was higher in fish exposed to 4 and 6mg DON/kg for
6 weeks and in fish exposed to 6mg/kg for 8 weeks compared with
controls (Table 2).
For a number of clinical biochemical parameters: alkaline phos-
phatase, cholesterol, triglycerides, total proteins and albumin, exposure
to DON caused a linear dose-related decrease at all sampling time
Fig. 1. Average feed intake (g dry matter/week/fish) in post-smolt Atlantic salmon fed feed with different concentrations of deoxynivalenol (DON) or ochratoxin A
(OTA), and vaccinated after 3 weeks.
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points (Table 3). The most prominent impact on these parameters ap-
peared after 8 weeks of feeding. Compared with the control group,
triglycerides were decreased already in fish exposed to 1mg DON/kg
feed, whereas cholesterol, total proteins and albumin were lower in fish
at doses of 2mg DON/kg and above, and alkaline phosphatase was
lower in fish exposed to 6mg/kg and (Table 4). We found similar, but
less prominent effects on these parameters after 3 and 6 weeks.
AST showed a significant linear dose-related decrease at 8 weeks,
and bile acids a decrease at 3 and 8 weeks (Table 3). However, when
compared with control fish, DON did not significantly change the AST
values in any of the dose groups. Bile acids were significantly lower in
fish exposed to 2 and 6mg DON/kg feed at 8 weeks (Table 4).
Packed cell volume was measured at 8 weeks sampling only. A dose-
dependent reduction was observed in fish exposed to DON (Table 3).
Compared with control fish lower packed cell volume was observed in
fish exposed to DON in the feed at 2mg/kg and above (Table 4).
The impact of DON on the immune response was examined by de-
termining blood concentrations of antibodies against A. salmonicidae
before and following vaccination. A statistically significant dose-related
reduction in antibody levels was observed both before vaccination at 3
weeks and after, at 6 weeks of exposure to DON (Table 3), but no sig-
nificant difference between any of DON exposed groups and controls
were found (Table 4).
Various immune parameters measured as mRNA levels in the spleen
of fish from the group exposed to the highest DON feed concentration,
6mg/kg, did not differ from controls (Table 5).
Histopathological examination of the liver after 8 weeks revealed
some degree of vacuolization of hepatocytes in several fish both in the
experimental group and the control group. It was not possible to relate
the changes to the DON exposure.
3.4. BMD modeling
We used benchmark dose (BMD) modeling to estimate a reference
level for DON in feed, based on selected performance and/or health
parameters after 8 weeks feeding. The different models (Hills 3 and 5,
Exponential 3 and 5) had relatively close AIC values, the difference
between lowest and highest AIC being never larger than 4. It was lower
than 2, meaning the models were equivalently good, for weight, length,
AST, ALT, alkaline phosphatase, and antibodies.
Table 6 shows the best estimate of the lower bound of the BMD 95%
confidence interval (BMDL) assessed for performance parameters and
relative liver weight using a benchmark response (BMR) of 5%, i.e. 5%
change (BMDL05) and for blood parameters a BMR of 20% (BMDL20).
The effects on length, condition factor, and total protein and cholesterol
in plasma had a low BMDU/BMDL ratio (3, 7, 3, 15, respectively),
giving an acceptable BMD estimate, with a lowest BMDL5 of 0.5mg/kg
for condition factor (Fig. 3) and a BMDL20 of 0.3 mg/kg for total pro-
tein in plasma (Fig. 4). The lowest BMDLs for DON obtained were those
on antibodies (0.01mg/kg), alkaline phosphatase (0.05mg/kg) and
relative liver weight (0.05mg/kg). However these parameters had a
high BMDU/BMDL ratio (404, 75, and 74, respectively), indicating a
wide range of the confidence interval and therefore a high uncertainty
in the BMD assessment. BMD modeling confirmed that there was a
significant effect of DON dose on body weight, but the fits with Hill and
exponential functions were not good enough to estimate a BMDL value
from that parameter.
3.5. OTA effects on selected health indices
For OTA, no significant dose-related effect on absolute or relative
liver weight was shown (Table 3) and no corresponding effects were
found in any group compared with controls (Table 2).
Also, for clinical chemical parameters in fish exposed to OTA, there
were less dose-related effects than in fish exposed to DON. Alkaline
phosphatase, cholesterol, total protein, albumin and AST showed line-
arly significant increases with OTA dose, mostly after 3 weeks
(Table 3). However the few significant changes, when compared with
controls, were mainly observed after 8 weeks (Table 4). Lower trigly-
cerides were found in fish exposed to OTA at 0.2 and 2.4 mg/kg, and
reduced total protein and albumin were found at 1.6 mg/kg at 8 weeks.
Fish exposed to OTA did not show a linear dose-response relation for
packed cell volume, but when comparing OTA exposed fish with con-
trols, packed cell volume was significantly reduced in fish exposed to
0.4 mg OTA/kg (Tables 3 and 4).
OTA exposure did not result in any dose-related effect on antibody
titers against A. salmonicidae and there was no significant difference in
OTA groups compared with controls (Tables 3 and 4). For two immune
genes, mRNA levels were influenced by the highest OTA feed con-
centration, i.e. 2.4mg/kg (Table 5). Compared with controls, the OTA
fed group had increased expression of IFNγ at 3 weeks. Expression of
Ki67 was increased at 6 weeks indicating proliferation of immune cells
in the spleen.
After 8 weeks of OTA exposure, no dose-response relationship was
found with BMD modeling for the various parameters.
Histopathological examination of the liver after 8 weeks revealed
some degree of vacuolization of hepatocytes in several fish both in the
experimental groups exposed to OTA and the control group. It was not
possible to determine whether these changes were treatment related.
Fig. 2. Dose-response of DON and OTA on feed efficiency in post-smolt Atlantic
salmon fed feed with different concentrations of DON or OTA for up to 8 weeks.
The results are calculated as weight gain/dry matter consumed after 3, 6 and 8
weeks. Linear fit and 95% confidence lines are shown.
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4. Discussion
4.1. Effect level of DON and OTA in the post-smolt salmon
The present study revealed that exposure to DON at the dosages
employed may affect several health parameters of post-smolt salmon.
These included a reduction in feed intake, weight gain, condition factor,
feed efficiency, packed cell volume and plasma levels of alkaline
phosphatase, cholesterol, triglycerides, total proteins, albumin and
specific immunoglobulins, as well as increased relative liver weight.
The mechanism of feed refusal in fish is not established, but could be
similar to that seen for feed refusal and vomiting in other animal spe-
cies in which this effect in mediated by a central nervous serotonergic
mechanism. Impaired haematopoiesis, reduced production of ery-
throcytes and leukocytes that were not measured, with subsequent af-
fection of immune function is a pattern consistent with gastrointestinal
dysfunction and impaired protein synthesis.
Similarly, such a pattern is consistent with observed effects in farm
animal species dietary exposed to DON (VKM, 2013; EFSA, 2017a). The
effect level of DON in the post-smolt salmon seem to be quite similar to
the effect level observed in other intensively produced animal species
such as growing pigs and broiler chickens. For growing pigs the LOAEL
may vary considerably from one study to another, ranging from 0.35 to
2mg/kg feed causing reduced feed intake as critical effect (Eriksen and
Pettersson, 2004). For chicken a LOAEL of 1.7mg/kg feed was identi-
fied with histopathological effects in the small intestine, lower weight
gain and altered immune responses after vaccination (Yunus et al.,
2012).
Compared with control fish, most effects of DON were found after 8
weeks feeding, and at the two highest concentrations (4 and 6mg DON/
kg feed). However, some effects were also found from 2mg DON/kg
feed, such as reduced packed cell volume, cholesterol, total proteins
and albumin. Furthermore, reduced triglycerides were seen already at
1mg/kg, but this effect was not consistently significant at all higher
dosage levels. The significantly reduced packed cell volume and clinical
biochemical effects at DON concentration 2mg/kg feed and the con-
sistency of these effects in relation to dose suggests 2mg/kg feed to be
the lowest observed adverse effect level (LOAEL) and 1mg/kg feed as
the no-observed adverse effect level (NOAEL) for DON in the present
study. The lowest BMDLs for DON with an acceptable certainty were
found for condition factor with BMDL05 of 0.5 mg/kg, and for plasma
level of total protein with BMDL20 of 0.3mg/kg.
A biological relation between increased relative liver weight and
decreased alkaline phosphatase, cholesterol, total proteins and albumin
seemed to occur as relatively highly significant inverse correlations
were present between relative liver weight and these parameters
Table 2
Performance parameters in post-smolt Atlantic salmon exposed to deoxynivalenol (DON) or ochratoxin A (OTA) in their feed for up to 8 weeks. Median (and min.-
max.) of individual body weight and length, condition factor and relative liver weight are shown, and significant differences from control fish (p < 0.05) with
Bonferoni approximation are indicated with an asterisk. N= 22 fish sampled at the start of the experiment. N= 10 fish per group sampled at 3, 6 and 8 weeks.
Group Body weight g Body length cm Condition Factor g.cm−3/100 Relative liver weight %
Start
Control 56 (50–72) 17.1 (16.0–19.0) 1.13 (0.93–1.27) 1.41 (0.98–1.86)
3 weeks
Control 76 (70–84) 18.7 (18.0–19.6) 1.15 (0.99–1.22) 1.37 (1.03–1.70)
DON 0.5mg/kg 72 (62–82) 18.2 (17.5–19.1) 1.19 (1.03–1.27) 1.32 (1.10–1.99)
DON 1mg/kg 71 (56–92) 18.4 (17.0–19.5) 1.13 (1.04–1.38) 1.29 (1.08–1.43)
DON 2mg/kg 71 (59–82) 18.8 (17.5–19.5) 1.10 (1.00–1.17) 1.33 (0.89–1.63)
DON 4mg/kg 67 (57–82) 18.3 (17.6–19.9) 1.08 (1.01–1.23) 1.36 (1.18–1.74)
DON 6mg/kg 62 (52–77)* 18.7 (17.0–19.5) 1.04 (0.92–1.24) 1.17 (0.97–2.12)
OTA 0.2mg/kg 73 (60–95) 18.7 (17.8–20.1) 1.12 (1.00–1.37) 1.47 (1.12–2.15)
OTA 0.4mg/kg 78 (62–90) 19.3 (17.3–19.9) 1.13 (1.03–1.23) 1.27 (1.11–1.47)
OTA 0.8mg/kg 72 (59–84) 18.4 (17.0–19.3) 1.15 (1.03–1.21) 1.40 (0.97–1.79)
OTA 1.6mg/kg 82 (69–100) 19.2 (17.7–20.3) 1.21 (1.10–1.32) 1.22 (0.98–1.46)
OTA 2.4mg/kg 77 (67–92) 19.1 (18.2–19.8) 1.14 (1.00–1.28) 1.28 (0.99–1.59)
6 weeks
Control 99 (87–111) 20.3 (19.5–21.3) 1.19 (1.12–1.27) 1.19 (1.01–1.29)
DON 0.5mg/kg 99 (79–139) 19.9 (19.2–21.9) 1.24 (1.05–1.34) 1.20 (1.03–1.49)
DON 1mg/kg 99 (58–131) 20.2 (17.1–21.9) 1.17 (1.08–1.42) 1.26 (1.05–1.59)
DON 2mg/kg 97 (74–120) 19.8 (18.5–22.0) 1.21 (1.10–1.31) 1.21 (0.97–1.66)
DON 4mg/kg 93 (67–105) 20.1 (17.2–21.0) 1.12 (1.07–1.32) 1.47 (1.17–2.01)*
DON 6mg/kg 68 (50–96)* 18.5 (16.8–20.4)* 1.06 (1.03–1.18)* 1.61 (1.10–2.04)*
OTA 0.2mg/kg 96 (64–117) 19.6 (17.1–21.3) 1.24 (1.08–1.39) 1.34 (1.00–1.66)
OTA 0.4mg/kg 114 (75–137) 21.1 (17.8–22.5) 1.21 (1.10–1.33) 1.26 (0.93–1.46)
OTA 0.8mg/kg 87 (51–117) 18.7 (16.8–21.3) 1.21 (1.08–1.44) 1.27 (1.09–1.54)
OTA 1.6mg/kg 116 (80–126) 20.9 (18.6–22.6) 1.23 (1.09–1.38) 1.22 (1.00–1.51)
OTA 2.4mg/kg 99 (81–129) 20.4 (18.7–21.9) 1.24 (1.12–1.31) 1.24 (1.06–1.49)
8 weeks
Control 123 (102–159) 21.3 (20.0–23.8) 1.28 (1.17–1.32) 1.24 (0.99–1.36)
DON 0.5mg/kg 101 (82–136) 20.7 (18.7–22.7) 1.18 (1.09–1.34) 1.25 (1.01–1.43)
DON 1mg/kg 119 (111–138) 21.8 (21.0–23.0) 1.15 (1.12–1.26) 1.26 (1.08–1.53)
DON 2mg/kg 117 (85–139) 21.7 (19.5–23.0) 1.19 (1.12–1.26) 1.32 (1.11–1.62)
DON 4mg/kg 113 (59–121) 21.1 (17.3–22.3) 1.13 (1.03–1.30)* 1.51 (0.97–2.53)
DON 6mg/kg 81 (74–92)* 19.6 (19.4–20.7)* 1.05 (0.97–1.15)* 1.69 (1.12–2.19)*
OTA 0.2mg/kg 122 (108–141) 21.6 (20.5–22.7) 1.21 (1.13–1.37) 1.32 (1.05–1.91)
OTA 0.4mg/kg 131 (101–160) 21.7 (20.6–24.1) 1.20 (1.11–1.45) 1.25 (0.94–1.46)
OTA 0.8mg/kg 117 (103–153) 21.1 (20.0–23.5) 1.23 (1.11–1.32) 1.63 (1.09–2.27)
OTA 1.6mg/kg 124 (103–179) 21.8 (20.4–23.8) 1.21 (1.12–1.34) 1.12 (1.08–1.36)
OTA 2.4mg/kg 126 (103–179) 22.3 (20.4–23.8) 1.21 (0.98–1.34) 1.13 (1.09–1.52)
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(r=−0.48 to −0.56 in all DON exposed and control fish sampled
during 3–8 weeks, N= 180).
For the OTA dosages employed, even if the highest dose was 10
times the standard maximum concentrations in fish feed in EU
(European Commission, 2006), the present study did not reveal similar
dose-response effects as shown for DON. The OTA-response in the ju-
venile Atlantic salmon is different from that of other intensively pro-
duced animal species such as growing pigs and broiler chickens (EFSA,
2004; EFSA, 2006; VKM, 2013). In growing pigs a LOAEL for OTA at
0.2 mg/kg feed was established based on nephrotoxic effects (VKM,
2013), whereas 0.025mg/kg was indicative as LOAEL based on per-
formance (Malagutti et al., 2005). In chicken a LOAEL at 0.5 mg/kg
feed based on immune function was reported (VKM, 2013), whereas a
LOAEL of 0.1 mg/kg for immunological effects has been indicated in
male chicken (Ul-Hassan et al., 2012).
In the post-smolt salmon, the few significant effects of OTA ex-
posure compared with controls were mainly found at sampling point 8
weeks and not related to dose. IFNγ and Ki67 expression in the spleen,
when tested at highest dosage level only, were increased compared with
controls after 3 and 6 weeks, respectively. The increased levels of these
gene markers may indicate an immune activation but the functional
effect is not determined as reagents for the proteins are not available.
Anyway, a possible consequence for the fish' immune function from
elevation of these biomarkers is not known.
As no effects on performance or other adverse clinical effects were
revealed and the subclinical effects lacked consistency across doses, the
NOAEL for OTA in the present study on post-smolt salmon is 2.4mg
OTA/kg feed.
4.2. Comparison with DON effects in other fish studies
Other studies on DON in Atlantic salmon are not available in the
scientific databases. In the following section we will compare our re-
sults of DON exposure in Atlantic salmon with those obtained in other
fish species. See Table 7.
In studies of DON in another salmonidae, rainbow trout, fed up to
12.9mg DON/kg feed, Woodward et al. (1983) and Hooft et al. (2011)
showed that juvenile rainbow trout were highly sensitive for DON. No
mortality was observed during these experiments, which is in ac-
cordance with the findings of feed refusal of highly DON contaminated
feed. Both studies report a linear dose-response inhibition of perfor-
mance, and Woodward et al. (1983) showed inhibited weight gain from
1.0mg/kg feed. Hooft et al. (2011) reported that DON caused a dose-
dependent inhibition of whole body protein content, nitrogen and en-
ergy recovery and retention without apparently affecting digestibility of
crude protein or gross energy. Furthermore, they found histopatholo-
gical changes in livers of fish fed DON at 1.4mg/kg and above. There
were no substantial pathological changes in the distal intestine. They
did not determine packed cell volume or other hematology parameters.
In our study, the impact of DON on performance in juvenile salmon
showed a similar pattern as those from the above studies on juvenile
rainbow trout. Our results showing reduced concentrations of plasma
proteins (total protein and albumin) and lipids (triglycerides and cho-
lesterol) with increasing doses of DON may be a result of reduced
synthesis of proteins or lipoproteins in the liver. This is consistent with
the reduced whole body protein and, nitrogen and energy retentions
reported by Hooft et al. (2011).
Ryerse et al. (2015, 2016) in their studies of DON in juvenile
rainbow trout focused mainly on mortality after challenging with
Table 3
Linear fits for dose-response effects on performance, absolute and relative liver weight, clinical biochemical parameters and antibodies against Aeremonas salmo-
nicidae in blood plasma, and packed cell volume, in Atlantic salmon exposed to five concentrations of deoxynivalenol (DON) (0.5–6mg/kg) or ochratoxin A (OTA)
(0.2–2.4 mg/kg) or no toxins in their feed for up to 8 weeks. N=10 fish per dosage group at each sampling time.
Week 3 Week 6 Week 8
p Slope R2adj p Slope R2adj p Slope R2adj
DON
Body weight < 0.001 −1.71 0.20 <0.001 −4.62 0.28 < 0.001 −6.12 0.37
Body length ns 0.001 −0.23 0.15 0.001 −0.25 0.16
Condition factor 0.001 −0.02 0.17 <0.001 −0.02 0.27 < 0.001 −0.03 0.45
Liver weight ns ns ns
Relative liver weight ns <0.001 0.001 0.34 < 0.001 0.001 0.31
AST (log10) ns ns < 0.001 −0.05 0.17
ALT (log10) ns ns ns
Alkaline phosphatase < 0.001 −14.2 0.20 <0.001 −23.9 0.28 < 0.001 −28.0 0.35
Cholesterol < 0.001 −0.4 0.24 <0.001 −0.7 0.43 < 0.001 −0.8 0.51
Triglycerides < 0.001 −0.2 0.24 <0.001 −0.2 0.18 < 0.001 −0.2 0.18
Bile acids 0.024 −2.3 0.07 ns 0.034 −2.3 0.06
Total proteins 0.001 −1.3 0.16 <0.001 −3.6 0.41 < 0.001 −2.6 0.37
Albumin < 0.001 −0.7 0.17 <0.001 −2.0 0.44 < 0.001 −1.3 0.33
Antibodies 0.002 −0.01 0.13 0.016 −0.02 0.08 ns
Packed cell volume – – 0.001 −1.13 0.17
OTA
Body weight ns ns ns
Body length ns ns ns
Condition factor ns ns ns
Liver weight ns ns ns
Liver weight/body weight ns ns ns
AST (log10) 0.02 0.08 0.08 ns ns
ALT (log10) ns ns ns
Alkaline phosphatase < 0.001 40.1 0.18 0.040 25.9 0.05 ns
Cholesterol < 0.001 0.9 0.21 ns ns
Triglycerides ns ns ns
Bile acids ns ns
Total proteins 0.001 2.7 0.17 ns ns
Albumin < 0.001 1.4 0.18 ns ns
Antibodies ns ns ns
Packed cell volume – – ns
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Table 4
Clinical biochemical parameters (aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, cholesterol, triglycerides, bile acids, total
proteins, albumin) and antibodies against Aeremonas salmonicidae in blood plasma from Atlantic salmon exposed to deoxynivalenol (DON) or ochratoxin A (OTA) in
their feed for up to 8 weeks. Median concentrations (and min.-max.) are shown, and significant differences from control fish (p < 0.05) with Bonferoni approx-
imation are indicated with an asterisk. N= 10 fish per group sampled at 3, 6 and 8 weeks. N= 22 fish sampled at start of the experiment.
Group AST
U/L
ALT
U/L
Alk. phosph.
U/L
Cholesterol
mmol/L
Triglycerides
mmol/L
Bile acids
μmol/L
Tot. prot.
g/L
Albumin
g/L
Antibodies
OD units
PCV
%
Start
Control 183 (98–380) 18 (11–33) 113 (28–254) 4.3 (1.4–6.4) 0.7 (0.3–1.8) 0 (0–23) 27 (13–36) 14 (6–18) 0.03 (0–0.10) n.a.
3 weeks n.a.
Control 236 (140–601) 19 (9–43) 198 (112–254) 7.0 (4.9–8.2) 2.0 (1.3–2.6) 3 (0–49) 35 (31–40) 18 (16–20) 0.08 (0.02–0.15)
DON
0.5mg/kg
205 (92–511) 15 (9–52) 146 (18–218) 6.3 (3.1–8.6) 2.8 (1.1–4.1) 9 (0–24) 33 (22–39) 16 (11–21) 0.07 (0.02–0.14)
DON
1mg/kg
313 (133–749) 26 (10–85) 169 (105–284) 7.1 (4.1–9.4) 1.9 (1.2–3.2) 29 (0–93) 37 (28–47) 19 (14–23) 0.08 (0.02–0.14)
DON
2mg/kg
186 (113–704) 11 (7–87) 178 (84–212) 6.4 (4.0–7.9) 1.8 (0.8–2.9) 6 (2–18) 36 (31–38) 19 (16–20) 0.06 (0.01–0.16)
DON
4mg/kg
233 (107–499) 17 (10–59) 135 (91–215) 5.5 (3.4–7.0) 1.3 (0.9–1.9)* 2 (0–9) 31 (23–40) 16 (11–22) 0.02 (0.00–0.12)
DON
6mg/kg
377 (71–955) 16 (8–115) 76 (10–173)* 4.4 (0.9–5.8)* 1.4 (0.2–2.5) 1 (0–8) 28 (13–39) 13 (6–20) 0.03 (0.00–0.12)
OTA
0.2 mg/kg
165 (100–310) 13 (8–27) 135 (43–215)* 5.5 (2.8–8.8) 1.7 (0.7–2.3) 6 (0–34) 33 (19–44) 17 (10–21) 0.03 (0.00–0.10)
OTA
0.4 mg/kg
190 (84–297) 14 (5–25) 157 (82–261) 5.8 (3.8–7.7) 1.8 (1.0–2.9) 5 (1–73) 32 (26–35) 17 (13–18) 0.04 (0.01–0.09)
OTA
0.8 mg/kg
178 (122–433) 15 (9–35) 160 (34–400) 5.6 (3.3–9.0) 2.1 (0.9–3.1) 2 (0–62) 33 (26–51) 17 (13–25) 0.03 (0.01–0.08)
OTA
1.6 mg/kg
228 (170–998) 13 (10–82) 236 (130–349) 7.7 (6.5–9.4) 3.1 (1.6–4.3) 10 (1–64) 37 (34–44) 19 (18–22) 0.06 (0.01–0.19)
OTA
2.4 mg/kg
241 (164–709) 15 (12–56) 225 (183–404) 8.3 (5.8–9.7) 1.7 (1.4–3.1) 6 (2–62) 40 (33–43) 21 (17–22) 0.09 (0.01–0.14)
6 weeks n.a.
Control 215 (170–277) 10 (6–19) 234 (159–308) 7.3 (6.0–9.0) 2.6 (1.5–4.1) 6 (1–50) 44 (35–49) 23 (19–26) 0.24 (0.09–0.43)
DON
0.5mg/kg
262 (199–440) 16 (13–25) 246 (73–418) 8.2 (4.7–10.3) 3.5 (1.1–4.1) 5 (0–25) 46 (40–55) 25 (22–30) 0.15 (0.09–0.31)
DON
1mg/kg
262 (211–582) 16 (1–38) 241 (180–358) 7.9 (7.2–11.1) 3.0 (1.2–4.4) 18 (2–94) 49 (44–59) 26 (23–30)* 0.25 (0.11–0.63)
DON
2mg/kg
234 (146–363) 15 (1–25) 241 (82–331) 7.1 (5.5–8.3) 2.4 (0.9–3.3) 11 (2–44) 41 (35–59) 21 (19–26) 0.15 (0.07–0.49)
DON
4mg/kg
224 (55–268) 10 (3–17) 211 (26–268) 5.5 (0.7–9.8) 1.7 (0.4–4.3) 8 (2–41) 39 (9–54) 21 (4–29) 0.09 (0.00–0.47)
DON
6mg/kg
198 (74–5540) 18 (6–327) 91 (17–305)* 3.8 (1.0–5.8)* 1.6 (0.6–3.2) 5 (0–38) 27 (10–40)* 14 (5–22)* 0.12 (0.02–0.33)
OTA
0.2 mg/kg
209 (102–473) 11 (1–32) 246 (67–349) 6.5 (2.6–8.5) 2.7 (0.4–5.2) 8 (0–19) 42 (19–50) 21 (10–24) 0.19 (0.07–0.44)
OTA
0.4 mg/kg
227 (185–357) 14 (10–23) 299 (149–375) 8.1 (7.0–9.8) 2.1 (1.1–6.1) 12 (2–133) 46 (38–58) 25 (20–30) 0.31 (0.06–0.48)
OTA
0.8 mg/kg
247 (160–342) 16 (12–24) 190 (48–334) 6.6 (3.8–8.6) 2.7 (1.0–4.5) 9 (0–114) 44 (26–53) 22 (14–26) 0.22 (0.06–0.61)
OTA
1.6 mg/kg
275 (215–344) 16 (11–25) 265 (202–405) 7.4 (5.7–10.0) 3.1 (1.7–4.6) 15 (7–140) 42 (34–53) 22 (18–28) 0.16 (0.05–0.50)
OTA
2.4 mg/kg
233 (162–474) 13 (9–25) 281 (213–420) 8.0 (5.4–10.8) 2.4 (1.0–3.9) 14 (3–90) 44 (39–57) 23 (21–30) 0.16 (0.08–0.78)
8 weeks
Control 269 (172–475) 10 (7–19) 305 (223–471) 9.4 (7.5–13.6) 3.2 (1.8–5.4) 23 (6–114) 47 (40–64) 23 (20–32) 0.29 (0.14–0.81) 45 (41–57)
DON
0.5mg/kg
259 (157–313) 13 (6–20) 257 (184–409) 7.8 (6.9–10.0) 4.0 (2.8–5.6) 10 (2–18) 42 (37–53) 22 (19–25) 0.23 (0.15–0.72) 44 (29–49)
DON
1mg/kg
298 (193–626) 15 (7–40) 300 (224–397) 8.6 (7.6–9.8) 1.8 (1.3–3.3)* 4 (1–65) 41 (37–50) 22 (19–25) 0.26 (0.13–0.48) 41 (35–50)
DON
2mg/kg
220 (102–385) 8 (6–26) 235 (95–303) 7.6 (4.4–9.2)* 2.3 (1.7–3.8) 5 (1–14)* 39 (23–45)* 20 (12–23)* 0.24 (0.04–0.93) 39 (30–48)*
DON
4mg/kg
209 (47–376) 8 (3–18) 200 (15–358) 7.5 (1.4–8.7)* 2.4 (0.5–5.5) 13 (1–43) 40 (12–47)* 20 (5–25) 0.13 (0.04-0.49) 39 (32–48)*
DON
6mg/kg
148 (45–635) 10 (4–43) 123 (51–272)* 4.7 (2.4–6.5)* 1.8 (1.0–2.5)* 3 (2–13)* 30 (18–42)* 15 (9–22)* 0.26 (0.04–0.65) 38 (31–44)*
OTA
0.2 mg/kg
203 (168–276)* 7 (5–18) 276 (223–533) 8.6 (6.8–9.6) 1.7 (1.0–3.5)* 4 (1–52)* 42 (37–45) 21 (19–24) 0.30 (0.04–0.46) 38 (32–50)
OTA
0.4 mg/kg
247 (184–508) 9 (7–42) 269 (195–352) 8.5 (7.2–10.0) 2.1 (1.6–4.5) 5 (3–61) 40 (36–47) 21 (19–24) 0.32 (0.14–0.94) 39 (32–42)*
OTA
0.8 mg/kg
227 (143–304) 11 (8–17) 287 (61–468) 7.9 (4.0–10.2) 2.3 (1.4–3.5) 4 (0–97)* 41 (23–50) 22 (11–26) 0.15 (0.03–0.52) 44 (38–52)
(continued on next page)
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Flavobacterium psychrophilum and found a significant reduction in cu-
mulative percent mortality in groups fed DON. The mortality was sig-
nificantly reduced both when compared with a pair-fed control group
and a normally fed control group. Also the pair-fed control group had a
reduced mortality, which illustrated that reduced amount of feed per se
also had a positive effect, and not only exposure to DON which had an
independent effect.
Matejova et al. (2014, 2015) fed DON 2mg/kg to one-year old
rainbow trout and found some biochemical and immunological effects
such as reduced mean corpuscular hemoglobin (MCH), as well as his-
topathological effects in the kidney. They did not report any significant
effects on performance, relative liver weight, liver histopathology or
packed cell volume. No difference between DON exposed- and control
groups was found with respect to specific IgM level in plasma when
tested two weeks after vaccination with Yersinia ruckeri type 1 during
the feeding experiment.
Juvenile red tilapia showed linearly decreased performance with
increased DON exposure (naturally contaminated wheat) up to
1.15mg/kg feed (Tola et al., 2015). The diets also contained lower
concentrations of zearalenone as well as other Fusarium metabolites
which might have had some influence on the results. No significant
effects on relative liver weight or packed cell volume were reported, but
there were trends of decreases in both parameters with increased ex-
posure to DON. No effect was found on AST or ALT. Histopathological
examination of liver revealed lesions (mainly subcapsular edema) in
some fish but apparently not related to the treatment.
In juvenile carp fed various amounts of DON up to 0.95mg/kg feed,
histopathological changes in liver were observed from 0.35mg/kg feed
and above, and some biochemical changes were seen in fish exposed to
higher DON concentrations (Pietsch et al., 2014a, 2014b). No effects of
DON were observed on performance or hematology parameters in-
cluding packed cell volume in fish. In subsequent studies of DON in
juvenile carp most immunological, biochemical and histopathological
effects were found within one or a few weeks and not observed at the
end of the DON exposure at eight weeks (Pietsch et al., 2015; Pietsch
and Burkhardt-Holm, 2015). Still no effect of DON was revealed on
performance.
In zebrafish given feed added up to 3mg DON/kg for up to 260 days
no effect was found on performance (Sanden et al., 2012). Changes in
gene markers of biochemical effects were observed. Fecundity data
showed a biphasic response pattern with dose, where fish fed a middle
DON concentration had significantly higher fecundity than control
Table 4 (continued)
Group AST
U/L
ALT
U/L
Alk. phosph.
U/L
Cholesterol
mmol/L
Triglycerides
mmol/L
Bile acids
μmol/L
Tot. prot.
g/L
Albumin
g/L
Antibodies
OD units
PCV
%
OTA
1.6 mg/kg
207 (148–298) 9 (7–13) 288 (255–409) 8.1 (6.2–9.8) 3.0 (1.9–4.1) 16 (6–53) 39 (35–47)* 20 (18–24)* 0.36 (0.03–0.56) 42 (38–47)
OTA
2.4 mg/kg
250 (201–1070) 11 (6–33) 323 (208–476) 9.1 (8.3–10.9) 2.1 (1.3–3.2)* 21 (3–33) 44 (41–46) 23 (21–25) 0.29 (0.13–0.68) 40 (34–46)
Table 5
Relative transcription (mRNA) in spleen (median (min.-max.)) from Atlantic salmon exposed to deoxynivalenol (DON), ochratoxin A (OTA) or no toxin (control).
N=10 for analyses of IgD, CD4 and CD8 (except for DON at 3 weeks and OTA at 8 weeks, where N=9), and N=8 for analyses of IFNγ and Ki67 (except for DON at
3 weeks and OTA at 8 weeks, where N=7). Significant difference from control fish is indicated with an asterisk.
IgD CD4 CD8 IFNγ Ki67
3 weeks
Control 0.109 (0.049–0.196) 0.006 (0.003–0.012) 0.014 (0.008–0.019) 0.011 (0.005–0.038) 0.018 (0.011–0.027)
DON 6mg/kg 0.103 (0.051–0.599) 0.005 (0.002–0.023) 0.018 (0.008–0.045) 0.028 (0.005–0.222) 0.016 (0.005–0.170)
OTA 2.4mg/kg 0.098 (0.051–0.507) 0.004 (0.002–0.014) 0.014 (0.008–0.03) 0.028 (0.017–0.067)* 0.025 (0.009–0.058)
6 weeks
Control 0.121 (0.079–0.243) 0.006 (0.004–0.009) 0.014 (0.009–0.027) 0.018 (0.010–0.084) 0.016 (0.012–0.032)
DON 6mg/kg 0.130 (0.002–0.332) 0.006 (0.005–0.015) 0.011 (0.002–0.027) 0.010 (0.008–0.051) 0.016 (0.009–0.024)
OTA 2.4mg/kg 0.148 (0.068–0.325) 0.005 (0.003–0.011) 0.016 (0.007–0.032) 0.034 (0.008–0.603) 0.036 (0.016–0.058)*
8 weeks
Control 0.137 (0.103–0.337) 0.007 (0.004–0.023) 0.017 (0.013–0.039) 0.031 (0.013–0.053) 0.031 (0.018–0.053)
DON 6mg/kg 0.253 (0.053–0.351) 0.008 (0.005–0.024) 0.022 (0.010–0.035) 0.323 (0.014–0.620) 0.035 (0.008–0.071)
OTA 2.4mg/kg 0.126 (0.072–0.398) 0.008 (0.005–0.047) 0.021 (0.007–0.070) 0.238 (0.016–0.683) 0.073 (0.022–0.319)
Table 6
Summary of benchmark dose (BMD) modeling with exponential and Hill
models in the study of post-smolt Atlantic salmon exposed to deoxynivalenol
(DON) in their feed for up to 8 weeks. The estimated threshold level of DON in
feed (mg/kg dry matter) which causes 5% or 20% effect on selected perfor-
mance and/or health parameters after 8 weeks feeding is shown as lower
(BMDL) and upper (BMDU) bounds of the BMD confidence interval. The sig-
nificance of the dose-response relationship, the selection of the best model, and
its fit to the experimental data, are based on the difference between the Akaike
information criteria (AIC) values, with a critical value of 2 units difference.
BMDL05 BMDU05 Ratio
BMDU/
BMDL
AIC
null -
AIC
min
AIC
min -
AIC
full
Best
model
Body weight Significant dose-response relation but
weak fit
31 3.2
(> 2)
Hill3
Length 2.3 6.2 3 10 1.7 Exp3
Condition
factor
0.5 3.3 7 35 0 Exp3
Relative liver
weight
0.05 3.6 74 24 −6 Exp3
BMDL20 BMDU20
AST 0.1 5.0 50 8 −4 Hill3
ALT No significant dose-response relation - 1
(< 2)
−2 Hill3
Alkaline
phospha-
tase
0.05 4.0 75 19 −5 Hill3
Cholesterol 1.5 4.2 3 37 −3 Exp3
Triglycerides Significant dose-response relation but
weak fit
13 5.3
(> 2)
Hill5
Total proteins 0.3 5.1 15 22 −6 Exp3
Albumin 0.01 5.4 618 18 −5 Exp3
Antibodies 0.01 3.5 404 3 −2 Hill3
Packed Cell
Volume
1.8 69.5 40 13 −6 Exp3
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group. Furthermore, there was a tendency of increased swimming ac-
tivity of larvae from adult fish fed the highest DON concentration.
Juvenile channel catfish exposed to DON have shown low suscept-
ibility to develop adverse effects (Manning et al., 2014). No effects on feed
intake, feed efficiency or weight gain were found compared with control
when fed DON up to 10mg/kg feed. Significantly reduced mortality were
found in fish fed higher DON concentrations compared with no or lower
DON concentrations after challenging with Edwardsiella ictaluri.
In comparison with other fish species such as juvenile rainbow
trout, red tilapia and carp, the juvenile Atlantic salmon in this study
showed fairly similar susceptibility to DON, but were more sensitive
than juvenile channel catfish and zebrafish. Older rainbow trout seem
to be less sensitive than the juveniles. DON showed a different effect
pattern among the studied fish species. In juveniles of salmon, rainbow
Fig. 3. Lowest benchmark dose (BMDL05), for condition factor (CF) assessed in two nested dose-response model families (Exponential model, left, and Hill model,
right) in Atlantic salmon fed graded level of deoxynivalenol (DON) for 8 weeks. Best fit is given according to AIC criteria given by EFSA (2017b). Model parameters of
best fit for both model families are given in legends, see proast model program description manual (EFSA, 2017b) for explanation abbreviations.
Fig. 4. Lowest benchmark dose (BMDL20), for plasma total protein assessed in two nested dose-response model families (Exponential model, left, and Hill model,
right) in Atlantic salmon fed graded level of deoxynivalenol (DON) for 8 weeks. Best fit is given according to AIC criteria given by EFSA (2017b). Model parameters of
best fit for both model families are given in legends, see proast model program description manual (EFSA, 2017b) for explanation abbreviations.
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trout and red tilapia the dominating effects were on feed intake and
efficiency, and weight gain, whereas no effects on performance were
seen in juveniles of carp, channel catfish and zebrafish. Other promi-
nent effects were histopathological changes in liver of rainbow trout,
tilapia and carp, which was an effect not observed in the Atlantic
salmon. In addition, various effects on biochemical and immunological
parameters were described in several species.
4.3. Comparison with OTA effects in other fish studies
Other studies on OTA in Atlantic salmon are not available in the
scientific databases. In the following section we will compare our re-
sults of OTA exposure in Atlantic salmon with those obtained in other
fish species. See Table 7.
Manning et al. (2003, 2005) have studied juvenile channel catfish
exposed to OTA in feed at concentrations up to 8mg/kg and the impact
on performance, haematological parameters, histopathology of liver
and kidney, and survival. A dose-related inhibition of weight gain was
found, and a significant effect was shown in fish fed 1.0 mg OTA/kg and
above, but not at 0.5 mg/kg. Furthermore, histopathological changes
were found in liver and kidney of fish fed 1.0mg/kg and above. Ju-
venile channel catfish challenged with Edwardsiella ictaluri after OTA
exposure in the feed, showed significantly higher mortality than control
fish. Thus, juvenile channel catfish, which were found very resistant to
DON with no performance effects from high DON exposure, were sus-
ceptible to OTA which caused reduced weight gain and histopatholo-
gical changes as dominating effects.
In juvenile Atlantic salmon we found the opposite in the present
study on DON and OTA. DON caused reduced performance effects and
various other dose-related effects, whereas OTA at doses used had no
impact on performance and no other clear dose-related or or time-de-
pendent effects.
5. Conclusions
A different effect pattern was found for the two toxins within the
dose levels examined, 0.5–6mg DON/kg and 0.2–2.4mg OTA/kg feed
to juvenile Atlantic salmon for up to 8 weeks exposure. For DON,
BMDLs of 0.3–0.5 mg/kg were obtained based on reduced performance
(condition factor) and clinical biochemical effect (reduced total pro-
tein) after 8 weeks exposure (Table 6). The NOAEL for DON was 1mg/
kg feed, based on reduced packed cell volume and clinical biochemical
effects (Table 4). The effect levels are similar to those previously ob-
served for juvenile rainbow trout, tilapia and carp, and also quite si-
milar to those observed for growing pigs and broiler chicken. Juvenile
channel catfish on the other hand appears to be less susceptible to DON
exposure via feed. The results indicate that the maximum re-
commended levels of DON in the current legislation for animal feed in
the EU at 5mg/kg feed (European Commission, 2006) is inappropriate
and not protective for salmon and most other examined fish species.
Neither does the Norwegian maximum level of DON in feed for fish at
2mg/kg (Norwegian Food Safety Authority, 2015) appear to be suffi-
ciently protective for juvenile Atlantic salmon against adverse effects.
For OTA in feed to juvenile Atlantic salmon no adverse effects were
seen at the highest dose used and therefore the NOAEL of 2.4mg/kg
from our study may be lower than the “true” NOAEL. A low sensitivity
to OTA exposure for adverse effects seems to be in accordance with our
finding of a rapid elimination and possibly induced elimination me-
chanisms of OTA in the salmon (Bernhoft et al., 2017). This is different
from the observations on sensitivity and dose-related effects in channel
catfish fed OTA, and also highly different from the sensitivity to OTA of
growing pigs and broiler chickens. The actual maximum recommended
level for OTA in fish feed in the EU of 0.25mg/kg (European
Commission, 2006) does protect the Atlantic salmon from adverse ef-
fects, as apparently the corresponding Norwegian maximum level of
1mg/kg fish feed (Norwegian Food Safety Authority, 2015) also does.Ta
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